EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access

Utility of 18 F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease

Diana M Lopez iD, Daniel M Huck iD, Sanjay Divakaran iD, Jenifer M Brown iD, Brittany N Weber iD, Mark Lemley iD, Valerie Builoff, Aakash Shanbhag iD, Zhou Lan, Christopher Buckley, Mouaz H Al-Mallah iD, Sharmila Dorbala iD und 3 weitere

Circulation: Cardiovascular Imaging · 2025

DOI: 10.1161/circimaging.125.018323 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Imaging, 2025. Verfasst von Diana M Lopez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Bri…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fractional Flow Reserve, Myocardial, Coronary Artery Disease, Myocardial Perfusion Imaging. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Absolute quantification of myocardial blood flow (MBF) on positron emission tomography perfusion imaging improves the identification of coronary artery disease (CAD). However, distinguishing MBF impairment due to obstructive CAD from nonobstructive CAD remains challenging. We aimed to evaluate the incremental diagnostic value of positron emission tomography derived relative flow reserve (RFR) in the diagnosis of obstructive CAD. METHODS: This is a post hoc analysis of the multicenter phase III trial of 18 F-flurpiridaz positron emission tomography. Patients with available MBF quantification were included. Reduced stress MBF (sMBF) was defined as sMBF below the median (2.2 mL/min per gram). Obstructive CAD on quantitative invasive coronary angiography was defined as ≥70% stenosis. RFR was calculated as a ratio of the minimal segment sMBF over the highest reference vascular territory sMBF. RFR performance for predicting obstructive CAD was evaluated through receiver operating characteristic analysis and the net reclassification index of multivariable regression models. RESULTS: The study included 231 patients (71% male; 56% with established CAD) drawn from the original cohort of 755 trial participants. No patients had 3-vessel CAD. In a per-vessel-based analysis, 82% of vessels with reduced sMBF had no obstructive CAD on invasive coronary angiography. RFR was significantly lower for vessels with obstructive CAD (0.55 versus 0.80; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyFractional Flow Reserve, MyocardialCoronary Artery DiseaseMyocardial Perfusion ImagingCoronary StenosisPyridazinesRadiopharmaceuticalsCoronary VesselsCoronary CirculationHumansMaleFemaleMiddle AgedAgedCoronary AngiographyPredictive Value of TestsDiagnosis, Differential

Stichwörter der Autor:innen

area under the curvecoronary artery diseasemyocardial perfusion imagingperfusion

Substanzen

PyridazinesRadiopharmaceuticalsBMS 747158-02

Autor:innen und Institutionen

  • Cardiovascular Imaging Program, Departments of Medicine and Radiology (D.M.L., D.M.H., S. Divakaran, J.M.B., B.N.W., S. Dorbala, R.B., M.F.D.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (M.L., V.B., A.S., P.S.).
  • Department of Radiology (Z.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Center for Clinical Investigation, Channing Division of Network Medicine (Z.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • GE Healthcare, Pharmaceutical Diagnostics, Buckinghamshire, United Kingdom (C.B.).
  • Houston Methodist DeBakey Heart and Vascular Center, TX (M.H.A.-M.).

ORCID-Profile: Diana M Lopez, Daniel M Huck, Sanjay Divakaran, Jenifer M Brown, Brittany N Weber, Mark Lemley, Aakash Shanbhag, Mouaz H Al-Mallah, Sharmila Dorbala, Ron Blankstein, Piotr Slomka, Marcelo F Di Carli

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • NIBIB NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Lopez, D. M., Huck, D. M., Divakaran, S., Brown, J. M., Weber, B. N., Lemley, M., Builoff, V., Shanbhag, A., Lan, Z., Buckley, C., Al-Mallah, M. H., Dorbala, S., Blankstein, R., Slomka, P., & Di Carli, M. F. (2025). Utility of 18 F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.125.018323

Vancouver

Lopez DM, Huck DM, Divakaran S, Brown JM, Weber BN, Lemley M, et al. Utility of 18 F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Imaging. 2025. doi:10.1161/circimaging.125.018323

BibTeX
@article{Lopez2025,
  author = {Lopez, Diana M and Huck, Daniel M and Divakaran, Sanjay and Brown, Jenifer M and Weber, Brittany N and Lemley, Mark and Builoff, Valerie and Shanbhag, Aakash and Lan, Zhou and Buckley, Christopher and Al-Mallah, Mouaz H and Dorbala, Sharmila and Blankstein, Ron and Slomka, Piotr and Di Carli, Marcelo F},
  title = {Utility of 18 F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2025},
  doi = {10.1161/circimaging.125.018323}
}
Kostenlos starten →